Compare Archer-Daniels-Midland Co (ADM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Summit Therapeutics Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.67 (market cap $38.78B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Archer-Daniels-Midland Co is far larger — about 3.2× Summit Therapeutics Inc's market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ADM | SMMT | |
|---|---|---|
Market Cap | $38.78B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $26.98 |
52-Week Low | $56.00 | $12.55 |
Enterprise Value | $47.03B | $11.39B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $79.72, down 0.96% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows solid fundamentals with a P/E of 21.98 and P/S of 0.48, while revenue for 2025 was $80.27B. Recent news highlights growth in biofuels and crushing margins, with the company raising its 2026 earnings outlook after a strong Q2.
The outlook is positive, supported by raised guidance and operational strength, but risks include execution challenges and margin pressures. Analysts maintain a consensus price target of $88.00, indicating potential upside from current levels amid a predominantly hold rating sentiment.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
